Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - Karyopharm

<a href="https://news.google.com/rss/articles/CBMiiwJBVV95cUxQWVVnOHlDNWtZdjlNaH…; target="_blank">Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis</a>&nbsp;&nbsp;<font color="#6f6f6f">Karyopharm</font>